Related Experiment Video

Updated: Aug 11, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

COX-2 inhibition prevents insulin-dependent diabetes in low-dose streptozotocin-treated mice

T Tabatabaie1, A M Waldon, J M Jacob

  • 1Free Radical Biology and Aging Research Program, Oklahoma Medical Research Foundation, 825 N. E. 13th Street, Oklahoma City, Oklahoma 73104, USA. Tahereh-Tabatabaie@omrf.ouhsc.edu

Biochemical and Biophysical Research Communications
|June 30, 2000
PubMed

Insights

Selective COX-2 inhibition prevents autoimmune diabetes in mice. This finding highlights the critical role of COX-2 in beta cell destruction and suggests potential preventive therapies for insulin-dependent diabetes mellitus.

Area of Science:

  • Immunology
  • Endocrinology
  • Pharmacology

Background:

  • Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease characterized by pancreatic beta cell destruction.
  • Inducible cyclooxygenase-2 (COX-2) is upregulated during inflammation and produces prostaglandin E(2) (PGE(2)), a key mediator.

Purpose of the Study:

  • To investigate the role of COX-2 in the autoimmune destruction of beta cells.
  • To evaluate the therapeutic potential of selective COX-2 inhibition in preventing IDDM.

Main Methods:

  • Administration of a selective COX-2 inhibitor, NS-398, to mice.
  • Induction of diabetes using multiple low doses of streptozotocin (STZ).
  • Histological examination of pancreatic islets to assess beta cell survival.

Main Results:

  • NS-398 treatment significantly prevented the onset of STZ-induced diabetes in mice.
  • Histological analysis confirmed that NS-398 protected beta cells from STZ-mediated destruction.
  • Delayed administration of NS-398 also conferred protection, but pre-treatment with a high toxic dose of STZ showed no protective effect.

Conclusions:

  • COX-2 activity is crucial for the autoimmune destruction of pancreatic beta cells.
  • Selective COX-2 inhibition demonstrates potential as a preventive strategy for IDDM.
  • Targeting COX-2 pathways may offer a novel therapeutic approach for autoimmune diabetes.

More Related Videos

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice06:41

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice

Published on: May 10, 2021

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...